Zacks: Brokerages Anticipate Diffusion Pharmaceuticals Inc (DFFN) Will Post Earnings of -$0.69 Per Share

Share on StockTwits

Analysts expect Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) to announce earnings of ($0.69) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Diffusion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.90) and the highest estimate coming in at ($0.48). Diffusion Pharmaceuticals posted earnings of ($0.75) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 8%. The business is scheduled to report its next earnings results on Monday, August 12th.

According to Zacks, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($2.25). For the next financial year, analysts forecast that the firm will report earnings of ($1.48) per share, with EPS estimates ranging from ($1.57) to ($1.39). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Diffusion Pharmaceuticals.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.09.

Several equities research analysts have issued reports on DFFN shares. HC Wainwright lifted their price target on Diffusion Pharmaceuticals to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. ValuEngine lowered Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 2nd.

DFFN stock traded down $0.26 during mid-day trading on Thursday, hitting $4.40. 46,909 shares of the stock were exchanged, compared to its average volume of 861,563. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.02. Diffusion Pharmaceuticals has a 12 month low of $1.83 and a 12 month high of $11.00.

An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 5.69% of the company’s stock.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Featured Article: What is the NASDAQ?

Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GPU Coin Tops One Day Trading Volume of $385.00
GPU Coin Tops One Day Trading Volume of $385.00
Brigham Minerals  & California Resources  Head-To-Head Review
Brigham Minerals & California Resources Head-To-Head Review
MaidSafeCoin  Trading Down 7.8% This Week
MaidSafeCoin Trading Down 7.8% This Week
GMB  Trading 7.8% Lower  This Week
GMB Trading 7.8% Lower This Week
Hyperion Tops 24-Hour Trading Volume of $590,936.00
Hyperion Tops 24-Hour Trading Volume of $590,936.00
Origin Sport Price Reaches $0.0083 on Major Exchanges
Origin Sport Price Reaches $0.0083 on Major Exchanges


 
© 2006-2019 Zolmax.